Reperfusion can be performed pharmacologically by the use of intravenous recombinant human tissue-type plasminogen activator (IV tPA; alteplase, Boehringer Ingelheim, Germany) within the first 4.5 h after stroke onset (3), and since 2015, by endovascular therapy (EVT) in case of an anterior circulation large-vessel occlusion (LVO) (4). The gene discussed is PLAT; the disease is stroke disorder.